Can Additional Drug Therapy Accelerate Response Time to Antidepressants
NCT00221494 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2015-06-01
Summary
Antidepressants are commonly prescribed and are effective for treating depression. However, they generally take 4-6 weeks for a therapeutic response. This study is evaluating whether simultaneous treatment with thyroid hormone or pindolol can decrease the response time ("getting better faster") in patients who are starting SSRI treatment.
Conditions
Interventions
- DRUG
-
citalopram + tiodothyronine, or + pindolol, or + placebo
Sponsors & Collaborators
-
University of California, Los Angeles
collaborator OTHER -
Mark Frye
lead OTHER
Principal Investigators
-
Mark A Frye, MD · University of California, Los Angeles
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-01-31
- Primary Completion
- 2006-06-30
Countries
- United States
Study Locations
More Related Trials
-
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
NCT01312922 ·Status: COMPLETED ·Phase: PHASE3
-
Thyroid Medication and Antidepressants for Treating Major Depression
NCT00208702 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Mild and Subthreshold Depressive Disorders
NCT00226642 ·Status: UNKNOWN ·Phase: PHASE4
-
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
NCT00232167 ·Status: TERMINATED ·Phase: PHASE3
-
Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder
NCT05271084 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.
NCT00421369 ·Status: COMPLETED ·Phase: NA
-
Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression.
NCT02223299 ·Status: WITHDRAWN ·Phase: NA
-
Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome
NCT00149825 ·Status: COMPLETED ·Phase: PHASE2
-
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
NCT00633399 ·Status: COMPLETED ·Phase: PHASE2
-
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
NCT00953745 ·Status: COMPLETED ·Phase: NA
-
Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.
NCT03435744 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients
NCT00018759 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
NCT04532749 ·Status: TERMINATED ·Phase: PHASE3
-
Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder
NCT00955955 ·Status: COMPLETED ·Phase: PHASE4
-
5-HTP and Creatine for Depression R33 Phase
NCT05895747 ·Status: RECRUITING ·Phase: PHASE2
-
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
NCT00581009 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Aripiprazole for the Augmentation of Antidepressant Therapy
NCT01429831 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder
NCT00451490 ·Status: WITHDRAWN ·Phase: NA
-
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
NCT01557946 ·Status: COMPLETED ·Phase: PHASE4
-
Ketamine and Nitroprusside for Depression
NCT03102736 ·Status: COMPLETED ·Phase: PHASE2
-
Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression
NCT00285727 ·Status: COMPLETED ·Phase: NA
-
Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression
NCT01670019 ·Status: COMPLETED ·Phase: PHASE4
-
Cognitive Therapy for Recurrent Depression
NCT00118404 ·Status: COMPLETED ·Phase: PHASE3
-
Combined N-of-1 Trials to Assess Open-Label Placebo Treatment for Antidepressant Discontinuation Symptoms
NCT05051995 ·Status: COMPLETED ·Phase: NA
-
Antidepressant Discontinuation in Treatment Resistant Depression
NCT03786614 ·Status: UNKNOWN ·Phase: NA